Progressive Multiple Sclerosis
Cervical Cord Atrophy and Long Term Disease Progression in Patients with Primary Progressive Multiple Sclerosis
... MATERIALS AND METHODS: Thirty-one patients with primary-progressive multiple sclerosis underwent 1.5T brain and spinal cord MR imaging at baseline and 6 –7 years later. The cervical spinal cord from ...
6
The Critical Role of Imaging in Primary Progressive Multiple Sclerosis
... Primary Progressive Multiple ...Keywords: Multiple sclerosis; Primary progressive type; Imaging *Correspondence: Yuyun Yueniwati, Radiology Department, Faculty of Medicine, Universitas ...
6
Fluoxetine in Progressive Multiple Sclerosis (FLUOX PMS): study protocol for a randomized controlled trial
... Background: Currently available disease-modifying treatments acting by modifying the immune response are ineffective in progressive multiple sclerosis (MS), which is caused by a widespread axonal ...
7
Case Report Primary progressive multiple sclerosis coexisting with patent foramen ovale: a case report
... of multiple sclerosis, primary progressive multiple sclerosis (PPMS) is char- acterized by a gradual, steady and relentless functional decline from onset, such as impaired walking due ...
5
Magnetic resonance imaging evaluation and therapeutic trials in primary progressive multiple sclerosis
... Although multiple sclerosis has been clinically characterised for over 150 years, its aetiology and pathophysiology are still poorly ...in multiple sclerosis has therefore remained in its ...
208
Extensive White Matter Dysfunction in Cognitively Impaired Patients with Secondary Progressive Multiple Sclerosis
... RESULTS: Forty-five patients with secondary-progressive multiple sclerosis (median age: 55 years, female/male: 27/18, median Expanded Disability Status Scale Score: 6.5) were prospectively recruited. ...
6
Serum S100B in primary progressive multiple sclerosis patients treated with
... primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon β-1a in subjects with ...primary progressive MS and whether Interferon ...
14
Adjustment modes in the trajectory of progressive multiple sclerosis: a qualitative study and conceptual model
... with progressive multiple sclerosis (MS) and developed a preliminary conceptual model of changes in adjustment over ...primary progressive MS and 21 with secondary progressive ...a ...
38
Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis
... secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312” (protocol number CBAF312A2304 sponsored by Novartis Phar- maceuticals; ...Excellence Multiple ...
15
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
... in progressive MS, as well as rituximab’s effect in subgroup analysis of PPMS patients, a Phase III trial has been conducted using ocrelizumab for primary progressive multiple sclerosis ...
15
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis
... Relapsing-remitting multiple sclerosis (RRMS) (orange triangles) vs control (green circles), (B) secondary progressive multiple sclerosis (SPMS) (blue squares) vs control (green ...
9
Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study
... This study suggests that a multimodal intervention is safe and may reduce fatigue and improve health-related quality of life of subjects with progressive MS. However, larger randomized controlled trials with ...
17
In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET
... with progressive MS were almost exclusively non-enhancing chronic lesions, this in- crease TSPO binding indicates that these are chronic ac- tive lesions ...
10
Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms
... Accordingly, there was no convincing superiority over the efficacy of the systemic steroid treatment. Some enrolled MS patients experienced a recent deterioration of symp- toms due to prior acute relapses and/or ongoing ...
5
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
... 27. Paap BK, Hundeshagen A, Hecker M, Zettl UK. An inventory of short term and long term changes in gene expression under interferon beta treatment of relapsing remitting MS patients. Curr Pharm Des. 2012;18(29):4475 – ...
8
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
... in progressive MS are the intrinsic pathogenetic differ- ences between SP and PP MS and the selective interaction of siponimod with types 1 and 5 S1PR, which are known to mediate protective effects on ...
5
The link of inflammation and neurodegeneration in progressive multiple sclerosis
... Recently, results of clinical trials have challenged the long-held belief that pathogenesis of PMS is more neu- rodegenerative than inflammatory, and distinct from these aspects in RRMS. Indeed, ocrelizumab, a human- ...
8
Focus on CNS Drug Development Treating secondary progressive multiple sclerosis. Simon Wilkinson, CEO
... • If MIS416 works in patients with SPMS, a disease where there is both tissue damage (the myelin) and ongoing inflammation inside the CNS, then MIS416 becomes a platform to be used in ot[r] ...
14
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis : views of patients and health professionals
... overall progressive illness, and lead to a sense of empowerment through recognising the experiences and resources that they have already developed in coping with ...
26
Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study
... was able to stand up from seated position by just pulling on the hand rail, had better foot clearance, and showed improved balance. Subject 11 showed dramatic improvement in her gait and balance within 3 months of ...
15